SCHEMBL31358797

SCHEMBL31358797

O=C1C(=Cc2ccc(-c3ccc(Cl)c([N+](=O)[O-])c3)o2)C(=O)c2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.56
MEN1 O00255 7/20 0.56
AKT1 P31749 1/20 0.54
MAPT P10636 8/20 0.50
TDP1 Q9NUW8 6/20 0.50
LMNA P02545 5/20 0.50
POLB P06746 5/20 0.50
NPSR1 Q6W5P4 4/20 0.50
KDM4E B2RXH2 4/20 0.50
PKM P14618 3/20 0.50
ALDH1A1 P00352 5/20 0.48
L3MBTL1 Q9Y468 4/20 0.48
HPGD P15428 4/20 0.48
RECQL P46063 3/20 0.48
MAPK1 P28482 3/20 0.48
BRAF P15056 2/20 0.48
MET P08581 1/20 0.48
MCL1 Q07820 3/20 0.47
MITF O75030 1/20 0.47
CACNA1B Q00975 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358776 0.84 SIRT2 (0.62) KMT2AMEN1AKT1MAPTTDP1
SCHEMBL31358804 0.83 MAPT (0.53) KMT2AMEN1MAPTTDP1LMNA
SCHEMBL31358796 0.83 PTPN5 (0.68) KMT2AMEN1MAPTTDP1LMNA
SCHEMBL31358693 0.81 AKT1 (0.58) KMT2AMEN1AKT1MAPTTDP1
SCHEMBL31358883 0.81 GSK3A (0.59) KMT2AMEN1MAPTTDP1LMNA
SCHEMBL31358680 0.81 KMT2A (0.58) KMT2AMEN1MAPTTDP1LMNA
SCHEMBL31358665 0.80 KMT2A (0.73) KMT2AMEN1MAPTTDP1LMNA
SCHEMBL31358774 0.80 BRAF (0.67) KMT2AMEN1AKT1MAPTTDP1
SCHEMBL31358745 0.80 MAPT (0.59) KMT2AMEN1MAPTLMNAPOLB
SCHEMBL31358872 0.79 KMT2A (0.60) KMT2AMEN1AKT1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 KMT2A 1043/4885MEN1 2467/4885AKT1 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.